Nipent (Pentostatin)

Pentostatin, the active ingredient in Nipent, is a purine analog presented as a sterile intravenous solution for injection use. It is employed in the treatment of certain lymphoid cancers, specifically chronic lymphocytic leukemia and hairy cell leukemia, targeting malignant lymphocytes.

GNH USA supplies Nipent as a licensed, GDP‑compliant international pharmaceutical product to hospitals, oncology centres, transplant units and pharmacies worldwide. The company ensures quality compliance with EU standards and provides reliable logistics for global distribution.

Pentostatin is used in hematologic malignancies that involve B‑cell lymphocytes.

- Chronic lymphocytic leukemia: reduces malignant lymphocyte proliferation and improves disease control. - Hairy cell leukemia: induces remission by targeting the disease‑specific B‑cell clone. - Other B‑cell lymphoid malignancies (off‑label): may be considered under specialist supervision when standard therapies are unsuitable.

Pentostatin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Fatigue: persistent tiredness during treatment. - Fever: transient temperature elevation. - Myelosuppression: reduced white blood cells, red cells, and platelets. - Infections: increased susceptibility to bacterial or viral infections. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Severe infections: opportunistic or life‑threatening infections. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Hepatotoxicity: significant elevation of liver enzymes or hepatic failure. - Anaphylaxis: acute allergic reaction requiring emergency care. - Renal impairment: acute kidney injury in susceptible patients.

When prescribing Pentostatin, clinicians should observe several precautionary measures to minimize risk.

- Baseline blood counts: obtain a complete blood count before initiation and monitor regularly. - Renal function: assess creatinine clearance and adjust use in renal impairment. - Hepatic function: evaluate liver enzymes; avoid in severe hepatic dysfunction. - Infection risk: screen for active infections and provide prophylactic antimicrobials as needed. - Pregnancy and lactation: avoid use; potential fetal toxicity is unknown. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pentostatin can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause severe infection. - Antimetabolites (e.g., methotrexate): additive myelosuppression. - High‑dose cytarabine: increased risk of severe bone marrow suppression.

Moderate Interactions (Monitor Closely): - Azoles (e.g., fluconazole): may raise Pentostatin plasma levels. - Allopurinol: can enhance toxicity by affecting purine metabolism. - NSAIDs: may exacerbate renal dysfunction.